DNA-based vaccines potentially represent a multi-billion-dollar business opportunity. We believe that Inovio's strong intellectual property and proprietary technology relating to electroporation-based DNA vaccines enables us to play a leadership role in advancing the development and potential commercialization of this important new generation of immunotherapies.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.